[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

Clinical Pharmacokinetics of Diclofenac

Therapeutic Insights and Pitfalls

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class. When given orally the absorption of diclofenac is rapid and complete. Diclofenac binds extensively to plasma albumin. The area under the plasma concentration-time curve (AUC) of diclofenac is proportional to the dose for oral doses between 25 to 150mg. Substantial concentrations of drug are attained in synovial fluid, which is the proposed site of action for NSAIDs. Concentration-effect relationships have been established for total bound, unbound and synovial fluid diclofenac concentrations.

Diclofenac is eliminated following biotransformation to glucoroconjugated and sulphate metabolites which are excreted in urine, very little drug is eliminated unchanged. The excretion of conjugates may be related to renal function. Conjugate accumulation occurs in end-stage renal disease; however, no accumulation is apparent upon comparison of young and elderly individuals. Dosage adjustments for the elderly, children or for patients with various disease states (such as hepatic disease or rheumatoid arthritis) may not be required.

Significant drug interactions have been demonstrated for aspirin (acetylsalicylic acid), lithium, digoxin, methotrexate, cyclosporin, cholestyramine and colestipol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ku EC, Wasvary JM, Cash WD. Diclofenac sodium (GP45840, Voltaren), a potent inhibitor of prostaglandin synthetase. Biochem Pharmacol 1975; 24: 641–3

    PubMed  CAS  Google Scholar 

  2. Brogden RN, Heel RC, Pakes GE, et al. Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 1980; 20: 24–48

    PubMed  CAS  Google Scholar 

  3. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244–85

    PubMed  CAS  Google Scholar 

  4. Goa KL, Chrisp P. Ocular diclofenac: a review of its pharmacology and clinical use in cataract surgery, and potential in other inflammatory ocular conditions. Drugs Aging 1992; 2(6): 473–86

    PubMed  CAS  Google Scholar 

  5. Fowler PD. Voltarol: diclofenac sodium. Clin Rheum Dis 1979; 5(2): 427–64

    Google Scholar 

  6. Geiger UP, Degen PH, Sioufi A. Quantitative assay of diclofenac in biological material by gas-liquid chromatography. J Chromatogr 1975; 111: 293–8

    PubMed  CAS  Google Scholar 

  7. El-Sayed YM, Abdel-Hameed ME, Suleiman MS. A rapid and sensitive high-performance liquid Chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. J Pharm Pharmacol 1988; 40: 727–9

    PubMed  CAS  Google Scholar 

  8. Moncrieff J. Extractionless determination of diclofenac sodium in serum using reversed-phase high-performance liquid chromatography with fluorimetric detection. J Chromatogr 1992; 577: 185–9

    PubMed  CAS  Google Scholar 

  9. Zhang SY, Zou HQ, Zhang ZY, et al. High-performance liquid Chromatographic method for the determination of diclofenac in serum and its pharmacokinetics in healthy volunteers. Acta Pharm Sinica 1994; 29(3): 228–31

    CAS  Google Scholar 

  10. Brombacher PJ, Cremers HMHG, Verheesen PE, et al. Quantitative determination of sodium-o-[(2,6-dichlorophenyl)-amino]phenylacetate (Diclofenac) in human blood plasma or serum. Arzneimittelforschung 1977; 27(8): 1597–9

    PubMed  CAS  Google Scholar 

  11. Ikeda M, Kawase M, Hiramatsu M, et al. Improved gas chromatgraphic method of determining diclofenac in plasma. J Chromatogr 1980; 183: 41–7

    PubMed  CAS  Google Scholar 

  12. Nielsen-Kudsk F. HPLC-Determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. Acta Pharmacol Toxicol 1980; 47: 267–73

    CAS  Google Scholar 

  13. Schumacher A, Geissler HE, Mutschier E. Quantitative bestimmung von diclofenac-natrium aus plasma durch absorptionsmessung mit hilfe der direkten auswertung von dunnschichtchromatogrammen. J Chromatogr 1980; 181: 512–5

    PubMed  CAS  Google Scholar 

  14. Chan KKH, Vyas KH, Wnuck K. A rapid and sensitive method for the determination of diclofenac sodium in plasma by high-performance liquid chromatography. Anal Lett 1982; 15(B21&22): 1649–63

    CAS  Google Scholar 

  15. Kadowaki H, Shiino M, Uemera I. Sensitive method for the determination of diclofenac in human plasma by gas chromatography-mass spectrometry. J Chromatogr 1984; 308: 329–33

    PubMed  CAS  Google Scholar 

  16. Derendorf H, Mullersman G, Barth J, et al. Pharmacokinetics of Diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. Eur J Clin Pharmacol 1986; 31: 263–5

    Google Scholar 

  17. Schneider W, Degen PH. Simultaneous determination of diclofenac sodium and its hydroxy metabolites by capillary column gas chromatography with electron-capture detection. J Chromatogr 1986; 383: 412–8

    PubMed  CAS  Google Scholar 

  18. Giachetti C, Poletti P, Zanola G. Determination of diclofenac in plasma samples: comparison between HRGC and HPLC. J High Resol Chromatogr Chrom Comm 1987; 10: 469–71

    CAS  Google Scholar 

  19. Owen SG, Roberts MS, Friesen WT. Rapid high-performance liquid Chromatographic assay for the simultaneous analysis of non-steroidal anti-inflammatory drugs in plasma. J Chromatogr 1987; 416: 293–302

    PubMed  CAS  Google Scholar 

  20. Leis HJ, Gleispach H, Malle E, et al. Femtomole analysis of diclofenac in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry using (18O2) diclofenac as internal standard. Biomed Environ Mass Spectrom 1988; 17: 307–10

    PubMed  CAS  Google Scholar 

  21. Leis HJ, Gleispach H, Nitsche V, et al. Femtomole analysis of diclofenac in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry using (18O2) diclofenac as internal standard. Biomed Environ Mass Spectrom 1988; 17: 437–41

    PubMed  CAS  Google Scholar 

  22. Raz I, Hussein Z, Samara E, et al. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1988; 26(5): 246–8

    PubMed  CAS  Google Scholar 

  23. Segura J, Mesres M, Aubets J, et al. Detection and quantification of non-steroidal anti-inflammatory agents by gas chromatography/mass spectrometry: diclofenac. Biomed Environ Mass Spectrom 1988; 16: 361–5

    PubMed  CAS  Google Scholar 

  24. Grandjean D, Beolar JC, Quincon MT, et al. Automated robotic extraction and subsequent analysis of diclofenac in plasma samples. J Pharm Sci 1989; 78(3): 247–9

    PubMed  CAS  Google Scholar 

  25. Mascher H. The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. Drug Des Deliv 1989; 4: 303–11

    PubMed  CAS  Google Scholar 

  26. Brunner LA, Luders RC. An automated method for the determination of diclofenac sodium in human plasma. J Chromatogr Sci 1991; 29: 287–91

    PubMed  CAS  Google Scholar 

  27. Del Puppo M, Cighetti G, Kienle MG, et al. Determination of diclofenac in human plasma by selected ion monitoring. Biol Mass Spectrom 1991; 20: 426–30

    PubMed  Google Scholar 

  28. Sioufi A, Richard J, Mangoni P, et al. Determination of diclofenac in plasma using a fully automated analytical system combining liquid-solid extraction with liquid chromatography. J Chromatogr 1991; 565: 401–7

    PubMed  CAS  Google Scholar 

  29. Wiese B, Hermansson J. Bioanalysis of diclofenac as its fluorescent carbazole acetic acid derivative by a post-column photoderivatization high-performance liquid Chromatographic method. J Chromatogr 1991; 567: 175–183

    PubMed  CAS  Google Scholar 

  30. Zecca L, Ferrario P, Costi P. Determination of diclofenac and its metabolites in plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991; 567: 425–32

    PubMed  CAS  Google Scholar 

  31. Santos SRCJ, Donzella H, Bertoline MA, et al. Simplified micromethod for the HPLC measurement of diclofenac in plasma. Braz J Med Biol Res 1992; 25: 125–8

    PubMed  CAS  Google Scholar 

  32. Seth BL. Comparative pharmacokinetics and bioavailability study of percutaneous absorption of diclofenac from two topical formulations containing drug as a solution or as an emulsion gel. Arzneimittel Forschung 1992; 42(1): 120–2

    PubMed  CAS  Google Scholar 

  33. Mueller EA, Kovarik JM, Koelle EU, et al. Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration. J Clin Pharmacol 1993; 33: 936–43

    PubMed  CAS  Google Scholar 

  34. Mendes GBB, Franco LM, Moreno RA, et al. Comparative bioavailability of two suspension formulations of potassium diclofenac in healthy male volunteers. Int J Clin Pharmacol Ther 1994; 82(3): 131–5

    Google Scholar 

  35. Maciá MA, Frias J, Carcas AJ, et al. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther 1995; 33(6): 333–9

    PubMed  Google Scholar 

  36. Borenstein MR, Xue Y, Cooper S, et al. Sensitive capillary gaschromatographic-mass spectrometric-selected-ion monitoring method for the determination of diclofenac concentrations in human plasma. J Chromatogr B 1996; 685: 59–66

    CAS  Google Scholar 

  37. Said SA, Sharaf AA. Pharmacokinetics of diclofenac sodium using a developed HPLC method. Arzneimittel Forschung 1981; 31(12): 2089–92

    PubMed  CAS  Google Scholar 

  38. Schneider W, Degen PH. Simultaneous determination of diclofenac sodium and its hydroxy metabolites by capillary column gas chromatography with electron-capture detection. J Chromatogr 1981; 217: 263–71

    PubMed  CAS  Google Scholar 

  39. Battista HJ, Wehinger G, Henn R, et al. Separation and identification of non-steroidal antirheumatic drugs containing a free carboxyl function using high-performance liquid chromatography. J Chromatogr 1985; 345: 77–89

    PubMed  CAS  Google Scholar 

  40. Sawchuck RJ, Maloney JA, Cartier LL, et al. Analysis of diclofenac and four of its metabolites in human urine by HPLC. Pharm Res 1995; 12(5): 756–62

    Google Scholar 

  41. Blum W, Faigle JW, Pfaar U, et al. Characterization of a novel diclofenac metabolite in human urine by capillary gas chromatography-negative chemical ionization mass spectrometry. J Chromatogr B 1996: 685: 251–63

    CAS  Google Scholar 

  42. Chan KKH, Vyas KH. Determination of diclofenac sodium in synovial fluid by high performance liquid chromatography. Anal Lett 1985; 18(B20): 2507–19

    CAS  Google Scholar 

  43. Zecca L, Ferrario P. Determination of diclofenac in plasma and synovial fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1989; 495: 303–8

    PubMed  CAS  Google Scholar 

  44. Blagbrough IS, Daykin MM, Doherty M, et al. High-performance liquid Chromatographic determination of diclofenac, ibuprofen and diclofenac in plasma and synovial fluid in man. J Chromatogr 1992; 578: 251–7

    PubMed  CAS  Google Scholar 

  45. Plavsic F, Culig J. Determination of serum diclofenac by high performance liquid chromatography by electrochemical detection. Hum Toxicol 1985; 4: 317–22

    PubMed  CAS  Google Scholar 

  46. Godbillon J, Gauron S, Metayer JP. High-performance liquid Chromatographic determination of diclofenac and its monohydroxylated metabolites in biological fluids. J Chromatogr 1985; 338: 151–9

    PubMed  CAS  Google Scholar 

  47. Rayanam IV, Pillai GK. Fused silica capillary column gas chromatography of diclofenac in human plasma and urine using electron capture detector. Indian Drugs 1988; 25(5): 191–4

    CAS  Google Scholar 

  48. Landsorp D, Janssen TJ, Guelen PJM, et al. High-performance liquid Chromatographic method for the determination of diclofenac and its hydroxy metabolites in human plasma and urine. J Chromatogr 1990; 528: 487–94

    Google Scholar 

  49. Averginos A, Karidas TH, Malamataris S. Extractionless high-performance liquid Chromatographic method for the determination of diclofenac in human plasma and urine. J Chromatogr 1993; 619: 324–9

    Google Scholar 

  50. Schmitz G, Lepper H, Estler C-J. High-performance liquid Chromatographic method for the routine determination of diclofenac and its hydroxy and methoxy metabolites from in vitro systems. J Chromatogr 1993; 620: 158–63

    PubMed  CAS  Google Scholar 

  51. Reigel M, Ellis PP. High-performance liquid Chromatographic assay for antiinflammatory agents diclofenac and flurbiprofen in ocular fluids. J Chromatogr B 1994; 654: 140–5

    Google Scholar 

  52. Riess W, Stierlin H, Degen P, et al. Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren. Scand J Rheumatol 1978; Suppl. 22: 17–29

    Google Scholar 

  53. Stierlin H, Faigle JW. Biotransformation of diclofenac sodium (Voltaren®) in animals and in man: II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica 1979; 9(10): 611–21

    PubMed  CAS  Google Scholar 

  54. Schweizer A, Willis JV, Jack DB, et al. Determination of total monohydroxylated metabolites of diclofenac in urine by electron-capture gas-liquid chromatography. J Chromatogr 1980; 195: 421–4

    PubMed  CAS  Google Scholar 

  55. Donato MG, Bayens W, Van Den Bossche W, et al. The determination of non-steroidal anti-inflammatory drugs in pharmaceuticals by capillary zone electrophoresis and micellar electrokinetic capillary chromatography. J Pharm Biomed Anal 1994; 12(1): 21–6

    PubMed  CAS  Google Scholar 

  56. Riess W, Sierlin H, Geiger UP, et al. Data on the pharmacokinetics and metabolism of diclofenac (Voltaren) in animals and man. In: Wagenhäuser FJ, editor. Chronic forms of polyarthritis. Bern: Huber, 1976: 302–19

    Google Scholar 

  57. John VA. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol®) in animals and man. Rheumatol Rehabil 1979; Suppl. 2: 22–37

    Google Scholar 

  58. Lau HSH, Chan K, Shum L, et al. Dose-proportionality of diclofenac sodium (Voltaren®) in man. Pharm Res 1989; 6: S–194

    Google Scholar 

  59. Kendall MJ, Thornhill DP, Willis JV. Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol®). Rheumatol Rehabil 1979; 2 Suppl.: 38–46

    PubMed  Google Scholar 

  60. Willis JV, Kendall MJ, Jack DB. The influence of food on the absorption of diclofenac after single and multiple oral doses. Eur J Clin Pharmacol 1981; 19: 33–7

    PubMed  CAS  Google Scholar 

  61. Willis JV, Jack DB, Kendall MJ, et al. The influence of food on the absorption of diclofenac as determined by the urinary excretion of the unchanged drug and its major metabolites during chronic administration. Eur J Clin Pharmacol 1981; 19: 39–44

    PubMed  CAS  Google Scholar 

  62. Willis JV, Kendall MJ, Flinn RM, et al. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979; 16: 405–10

    PubMed  CAS  Google Scholar 

  63. Willis JV, Kendall MJ. Pharmacokinetic studies on diclofenac sodium in young and old volunteers. Scand J Rheumatol 1978; Suppl. 22: 36–41

    Google Scholar 

  64. Crook PR, Willis JV, Kendall MJ, et al. The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease. Eur J Clin Pharmacol 1982; 21: 331–4

    PubMed  CAS  Google Scholar 

  65. Borghi C, Del Corno C, Palummeri E, et al. Pharmacokinetics, efficacy and safety of diclofenac: elderly vs non elderly arthritic patients [abstract 270]. Acta Pharmacol Toxicol 1986; 59Suppl. 5: 101

    Google Scholar 

  66. Gleiter CH, Antonin K-H, Bieck P, et al. Colonoscopy in the investigation of drug absorption in healthy volunteers. Gastrointest Endosc 1985; 31(2): 71–3

    PubMed  CAS  Google Scholar 

  67. Müller FO, Hundt HKL, Müller DG. Pharmacokinetic and pharmacodynamic implications of long-term administration of non-steroidal anti-inflammatory agents. Int J Clin Pharmacol 1977; 15(9): 397–402

    Google Scholar 

  68. Aylward M, Fowler PD, John V, et al. The influence of diclofenac sodium (Voltarol®) on free, protein-bound and total plasma L-tryptophan in adult healthy male subjects. Rheumatol Rehabil 1979; Suppl. 2: 47–59

    Google Scholar 

  69. Willis JV, Kendall MJ, Jack DB. A study of the effect of aspirin on the pharmacokinetics of oral and intravenous diclofenac sodium. Eur J Clin Pharmacol 1980; 18: 415–8

    PubMed  CAS  Google Scholar 

  70. Sioufi A, Godbillon J, Lecillon JB, et al. Influence of food and diet on gastrointestinal absorption of diclofenac sodium, sulfinpyrazone, cefroxadin, and cefalexin. In: Proceedings of the First European Congress of Biopharmaceutics and Pharmacokinetics; 1981 Jun 21–27; Paris. Paris: Clermont-Ferrrand, 1981: 447–55

    Google Scholar 

  71. Henrikson P-Á, Thilander H, Wåhlander LÅ. Absorption and effect of diclofenac-sodium after surgical removal of a lower wisdom tooth. Curr Ther Res 1982; 31(1): 20–6

    Google Scholar 

  72. Sioufi A, Stoerlin H, Schweizer A, et al. Recent findings concerning clinically relevant pharmacokinetics of diclofenac sodium. In: Kass E, editor. Voltaren: new findings. Proceeding of the 15th International Congress of Rheumatology; Paris, France; 1981 Jun 22. Bern: Hans Huber, 1982: 19–30

    Google Scholar 

  73. Zimmerer VJ, Tittor W, Degen P. Plasmaspiegel von diclofenac und urinausscheidung von diclofenac und metabolism bei leberkranken patienten. Fortschr Med 1982; 100(36): 683–8

    Google Scholar 

  74. Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol 1983; 12: 325–30

    PubMed  CAS  Google Scholar 

  75. Schumacher A, Faust-Tinnefeldt G, Geissler HE, et al. Untersuchungen potentieller interaktioneen von diclofenac-natrium (Voltaren®) mit den basis therapeutika gold, D-penicillamin, chloroquin, azathioprin und mit prednisolon. Aktuel Rheumatol 1983; 8: 79–83

    Google Scholar 

  76. Gross W, Kroh J, Krebs A, et al. Diclofenac sodium: blood concentration of the slow-release from and influence on the metabolism of kallikrein. Arzneimittel Forsching 1984; 34(2): 1327–9

    CAS  Google Scholar 

  77. Möller H, Stüber W, Ding R. Bio Verfugbarkeit, in vivo- und in vitro- Freisetzung von oralen diclofenac-retardfromen — 1. Mitteilung. Pharm Zeitung 1984; 129(41): 2387–92

    Google Scholar 

  78. Terhaag B, le Petit G, Richter K, et al. Zur beziehung von in-vitro- und in-vivo- untersuchungen beim menschen am beispiel von diclofenac-suppositorien. Pharmazie 1985; 40: 784–6

    PubMed  CAS  Google Scholar 

  79. Culig J, Plavsic F, Maslac B. Biolska raspolozivost oralnih preparata diklofenaka. Lijec Vjesn 1986; 108: 40–2

    PubMed  CAS  Google Scholar 

  80. Terhaag VB, Kirsch U, Le Petit G, et al. Zur bioVerfügbarkeit und zum pharmakokinetischen verhalten von diclofenac aus rewodina-dragees am menschen. Z Klin Med 1986; 41: 147–9

    CAS  Google Scholar 

  81. De Bernardi di Valserra M, Feletti F, Bertè F, et al. Lack of effect of a single-dose of sulglicotide on the bioavailability of diclofenac. Eur J Clin Pharmacol 1988; 34: 211–2

    PubMed  Google Scholar 

  82. Degen PH, Dieterle W, Schneider W, et al. Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. Xenobiotica 1988; 18(12): 1449–55

    PubMed  CAS  Google Scholar 

  83. El-Sayed Y, Suleiman MS, Hasan M, et al. Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. In J Clin Pharmacol Ther Toxicol 1988; 26(10): 487–91

    CAS  Google Scholar 

  84. Pillai GK, Rayanam IV. Pharmacokinetics and relative bioavailability of diclofenac in healthy volunteers. Indian Drugs 1988; 26(6): 280–2

    Google Scholar 

  85. Lau HSH, Chan K, Adair S, et al. Single dose bioavailability study of voltaren enteric coated tablets in humans. Pharm Res 1989; 6(9 Suppl.): S–232

    Google Scholar 

  86. Suleiman MS, Najib N, El-Sayed Y, et al. A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium. Int J Clin Pharmacol Ther Toxicol 1989; 27(6): 276–9

    PubMed  CAS  Google Scholar 

  87. Chan KKH, Mojaverian P, Ziehmer BA, et al. Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers. Pharm Res 1990; 7(10): 1026–32

    PubMed  CAS  Google Scholar 

  88. Maggi CA, Lualdi P, Mautone G. Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man. Eur J Clin Pharmacol 1990; 38: 207–8

    PubMed  CAS  Google Scholar 

  89. Korpela R, Olkkoola KT. Pharmacokinetics of intravenous diclofenac sodium in children. Eur J Clin Pharmacol 1990; 38: 293–5

    PubMed  CAS  Google Scholar 

  90. Landsorp D, Vree TB, Jansses TJ, et al. Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. Int J Clin Pharmacol Ther Toxicol 1990; 28(7): 298–302

    Google Scholar 

  91. Hasan MM, Najib NM, Rawashdeh NM, et al. Comparative bioavailability of two tablet formulations of diclofenac sodium in normal subjects. Int J Clin Pharmacol Ther Toxicol 1991; 29(3): 178–83

    PubMed  CAS  Google Scholar 

  92. Mustofa M, Suryawati S, Dwiprahasto I, et al. The relative bioavailability of diclofenac with respect to time of administration. Br J Clin Pharmacol 1991; 32: 246–7

    PubMed  CAS  Google Scholar 

  93. Neuvonen PJ. The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. Br J Clin Pharmacol 1991; 31: 263–6

    PubMed  CAS  Google Scholar 

  94. Sahajwalla CG, Bhatt AD, Bhatia SC, et al. Comparative bioavailability of slow release diclofenac (Voveran SR) with enteric coated tablet and internationally used Voltaren retard. J Assoc Physicians India 1991; 39(7): 546–8

    PubMed  CAS  Google Scholar 

  95. Terhaag B, Gramatte T, Hrdlcka P, et al. The influence of food on the absorption of diclofenac as a pure substance. Int J Clin Pharmacol Ther Toxicol 1991; 29(10): 418–21

    PubMed  CAS  Google Scholar 

  96. Karim A, Smith M. Biopharmaceutical profile of diclofenac-misoprostol combination tablet, Arthrotec®. Scand J Rheumatol 1992; Suppl. 96: 37–48

    Google Scholar 

  97. Thakker KM, Mangat S, Wagner W, et al. Effect of food and relative bioavailability following single doses of diclofenac 150 mg hydrogel bead (HGB) in healthy humans. Biopharm Drug Disp 1992; 13: 327–35

    CAS  Google Scholar 

  98. Alioth C, Blum RA, DAndrea DT, et al. Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCL in volunteers. Pharm Res 1993; 10(11): 1688–92

    PubMed  CAS  Google Scholar 

  99. Assandri A, Canali S, Giachetti C. Local tolerability and pharmacokinetic profile of a new transdermal delivery system, diclofenac hydroxyethylpyrrolidine plaster. Drugs Exp Clin Res 1993; 19(3): 89–95

    PubMed  CAS  Google Scholar 

  100. De Bernardi di Valserra M, Feletti F, Tripodi S, et al. Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac. Arzneimettel Forschung 1993; 43(1): 373–7

    Google Scholar 

  101. Hasan MM, Najib NM, Muti H. A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. Int J Clin Pharmacol Ther Toxicol 1993; 31(8): 389–91

    Google Scholar 

  102. Scheidel B, Blume H, Walter K, et al. Untersuchungen zur bioverfügarkeit von magensaftresistent überzogen diclofenac-zubereiungen. Arzneimittel Forschung 1993; 43(11): 1211–5

    PubMed  CAS  Google Scholar 

  103. Siegmund W, Scheuch E, Zschiesche M, et al. Potential pharmacokinetic interactions of nocloprost clathrate with retarded theophylline and enteric coated diclofenac after single and repeated premedication in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31(8): 407–14

    PubMed  CAS  Google Scholar 

  104. Ellis PP, Pfoff DS, Bloedow DC, et al. Intaocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. J Ocul Pharmacol 1994; 10(4): 677–82

    PubMed  CAS  Google Scholar 

  105. Gelderen MEM, Olling M, Barends DM, et al. The bioavailability of diclofenac from enteric coated products in healthy volunteers with normal and artificially decreased gastric acidity. Biopharm Drug Disp 1994; 15: 775–88

    Google Scholar 

  106. Kurowski M, Menninger H, Pauli E. The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. Int J Clin Pharmacol Ther 1994; 32(8): 433–40

    PubMed  CAS  Google Scholar 

  107. Scheidel B, Blume H, Walter K, et al. Untersuchungen zur bioverfügarkeit von magensaftresistent überzogen diclofenac-zubereiungen. Arzneimittel Forschung 1994; 44(1): 544–50

    PubMed  CAS  Google Scholar 

  108. Al-Balla SR, El-Sayed YM, Al-Meshal MA, et al. The effects of cholestyramine and colestipol on the absorption of diclofenac in man. Int J Clin Pharmacol Ther 1994; 32(8): 441–5

    PubMed  CAS  Google Scholar 

  109. Liu C-H, Kao V-H, Chen S-C, et al. In-vitro and In-vivo studies of the diclofenac sodium controlled-release matrix tablets. J Pharm Pharmacol 1995; 47: 360–4

    PubMed  CAS  Google Scholar 

  110. Hanses A, Spahn-Langguth H, Meiss F, et al. Pharmacokinetics and drug input characteristics for a diclofenac-codeine phosphate combination following oral and rectal administration. Arzneimittel Forschung 1996; 46(1): 57–63

    PubMed  CAS  Google Scholar 

  111. Ramakrishna S, Fadnavis NW, Diwan PV. Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans. Arzneimittel Forschung 1996; 46(1): 175–7

    PubMed  CAS  Google Scholar 

  112. Kovarik JM, Kurki P, Mueller E, et al. Diclofenac combined with cyclosporine in treatment of refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. J Rheumatol 1996; 23: 2033–8

    PubMed  CAS  Google Scholar 

  113. Cooper SA, Cowan A, Tallarida RJ, Hargreaves K, et al. The analgesic interaction of misoprostol with nonsteroidal antiinflammatory drugs. Am J Ther 1996; 3: 261–7

    PubMed  Google Scholar 

  114. Junior JP, Pierossi MDA, Muscara MN, et al. Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. Br J Clin Pharmacol 1997; 43: 104–8

    Google Scholar 

  115. Dittrich P, Brunner F. Bioavailability of slow release forms of indomethacin and diclofenac [abstract 3]. Arch Pharmacol 1981; 316 Suppl.: Rl

    Google Scholar 

  116. Raid LE, Sawchuck RJ, Cahn K, et al. Relative bioavailability and effects of food on plasma levels of diclofenac sodium following a single oral dose of Voltaren 100mg SR tablet. Pharm Res 1989; 6: S–229

    Google Scholar 

  117. Hengen N. Effects of codeine phosphate on the bioavailability of diclofenac Na from a fixed combination [abstract 400]. Arch Pharmacol 1985; 329 Suppl.: R100

    Google Scholar 

  118. Gaucher A, Netter P, Faure G, et al. Passage du diclofénac sodium dans le liquide synovial. Thérapie 1983; 38: 431–4

    PubMed  CAS  Google Scholar 

  119. Nishihata T, Kamada A, Sakai K, et al. Percutaneous absorption of diclofenac in rats and humans: aqueous gel formulation. Int J Pharm 1988; 46: 1–7

    CAS  Google Scholar 

  120. Cassidy J, Berner B, Chan K, et al. Human transbuccal absorption of diclofenac sodium from a prototype hydrogel delivery device. Pharm Res 1993; 10(1): 126–9

    PubMed  CAS  Google Scholar 

  121. Johnson AG, Quinn DI, O Day R. Non-steroidal antiinflammatory drugs. Med J Aust 1995; 163: 155–8

    PubMed  CAS  Google Scholar 

  122. Figueras A, Capella D, Casterl JM et al. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1994; 47: 297–303

    PubMed  CAS  Google Scholar 

  123. McNeill SC, Potts RO, Francoeur ML. Local enhanced topical delivery (LETD) of drugs: does it truly exist? Pharm Res 1992; 9: 1422–6

    PubMed  CAS  Google Scholar 

  124. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharm Exp Ther 1994: 268: 144–51

    CAS  Google Scholar 

  125. Radermacher J, Jentsch D, Scholl MA, et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol 1991; 31: 537–41

    PubMed  CAS  Google Scholar 

  126. Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 1995; 49(1): 33–5

    PubMed  CAS  Google Scholar 

  127. Riess VW, Schmid K, Botta L, et al. Die perkutane resorption von diclofenac. Arzneimittel Forschung 1986; 36(2): 1092–6

    PubMed  CAS  Google Scholar 

  128. Galzigna L, Mautone G, Lualdi P. Percutaneous absorption of diclofenac after topical application. Clin Trials J 1989; 26(5): 304–9

    Google Scholar 

  129. Sioufi A, Pommier F, Boschet F, et al. Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Disp 1994; 15: 441–9

    CAS  Google Scholar 

  130. Gallacchi G, Marcolongo R. Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion. Drugs Exptl Clin Res 1993; 24(3): 95–7

    Google Scholar 

  131. Friedman DI, Schwarz JS, Weisspapir M. Submicron emulsion vehicle for enhanced transdermal delivery of steroidal and nonsteroidal antiinflammatory drugs. J Pharm Sci 1995; 84: 324–9

    PubMed  CAS  Google Scholar 

  132. Kriwet K, Muller-Goymann CC. Diclofenac release from phospholipid drug systems and permeation through excised human stratum corneum. Int J Pharm 1995; 125: 231–42

    CAS  Google Scholar 

  133. Willimann H, Walde P, Luisi PL et al. Lecithin organogel as matrix for transdermal transport of drugs. J Pharm Sci 1992; 81: 871–4

    PubMed  CAS  Google Scholar 

  134. Dreher F, Walde P, Walther P, Wehrli E. Interaction of a lecithin microemulsion gel human stratum corneum and its effect on transdermal transport. J Control Release 1997; 45(2): 131–40

    CAS  Google Scholar 

  135. Quentin CD. Diclofenac-kammerwasserkonzentrationsbest-immung Bei kataraktoperation. In: Schott K, Jacobi KW, Freyler H, editors. Kongress der Deutschen Gesellscaft für intraokularlinsen implantation. Heidelberg: Springer-Verlag, 1991

    Google Scholar 

  136. Vickers FF, John VA. Corneal penetration of 0.1% diclofenac sodium opthalmic solutions in patients undergoing cataract surgery. J Clin Pharm 1990; 30: 835

    Google Scholar 

  137. Terhaag B, Hrdlicka P, Gramatte T, et al. Zum einfluß der nahrung auf die pharmakokinetik von diclofenac aus rewodina-25-dragees. Z Klin Med 1990; 45: 4443–6

    Google Scholar 

  138. Vidon N, Pfeiffer A, Godbillon J, et al. Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: application to diclofenac. Br J Clin Pharmacol 1989; 28: 121–4

    PubMed  CAS  Google Scholar 

  139. Wagner J, Sulc M. Bindung von diclofenacna (Voltaren®) an serumproteine verschiedener Spezies und interaktionen mit anderen pharmaka. Aktuel Rheumatol 1979; 4: 153–62

    Google Scholar 

  140. Chamourd J-M, Barre J, Urien S, et al. Diclofenac binding to albumin and lipoproteins in human serum. Biochem Pharmacol 1985; 34(10): 1695–1700

    Google Scholar 

  141. Chan KKH, Vyas KH, Brandt KD. In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci 1987; 76(2): 105–8

    PubMed  CAS  Google Scholar 

  142. Köhler G, Mohing W. Zur kinetik von diclofenacna in plasma und synovialflüssigkeit. Aktuel Rheumatol 1980; 5: 151–5

    Google Scholar 

  143. Fowler PD, Shadforth MF, Crook PR, et al. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol 1983; 25: 389–94

    PubMed  CAS  Google Scholar 

  144. Sioufi A, Schoeller J-P, Schwarzberg C, et al. Présence du diclofénac dans le plasma et le liquide synovial au cours de diverses affections rhumatismales. Gazette Méd 1984; 91(8): 88–9

    Google Scholar 

  145. Benson MD, Aldo-Benson M, Brandt KD. Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis and osteoarthritis. Semin Arthritis Rheum 1985; 15 (2 Suppl. 1): 65–7

    PubMed  CAS  Google Scholar 

  146. Liauw H, Walter S, Lee L, et al. Effects of diclofenac on synovial eicosanoid product formation in arthritic patients. J Clin Pharmacol 1985; 25: 455–74

    Google Scholar 

  147. Fowler PD, Dawes PT, John VA, et al. Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a l00mg slow-release formulation. Eur J Clin Pharmacol 1986; 31: 469–72

    PubMed  CAS  Google Scholar 

  148. Elmquist WF, Chan KKH, John VA. Transynovial distribution of diclofenac. Pharm Res 1989; 6: S–212

    Google Scholar 

  149. Elmquist WF, Chan KKH, Sawchuk RJ. Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. Pharm Res 1994; 11: 1689–97

    PubMed  CAS  Google Scholar 

  150. Owen SG, Francis HW, Roberts MS. Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol 1994; 38: 349–55

    PubMed  CAS  Google Scholar 

  151. Stierlin H, Faigle JW, Sallman A, et al. Biotransformation of diclofenac sodium (Voltaren®) in animals and in man: I. Isolation and identification of principal metabolites. Xenobiotica 1979; 9(10): 601–10

    PubMed  CAS  Google Scholar 

  152. Leeman T, Transon C, Dayer P. Cytochrome P450 TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1992; 52: 29–34

    Google Scholar 

  153. Faigle JW, Bottcher I, Godbillon J, et al. A new metabolite of diclofenac sodium in human plasma. Xenobiotica 1988; 18(10): 1191–7

    PubMed  CAS  Google Scholar 

  154. Menasse R, Hedwell PR, Kraetz J, et al. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol 1978; Suppl. 22: 5–16

    Google Scholar 

  155. Schneider HT, Nuernberg B, Dietzel K, et al. Biliary elimination of non-steroidal anti-inflammatory drugs in patients. Br J Clin Pharmacol 1990; 29: 127–31

    PubMed  CAS  Google Scholar 

  156. Seppälä E, Nissilä M, Isomäki H, et al. Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin Rheumatol 1985; 4(3): 315–20

    PubMed  Google Scholar 

  157. Fossaluzza V. A comparison of slow release diclofenac sodium and piroxicam on the morning stiffness of rheumatoid arthritis. Rheumatisomo 1983; 35: 270–2

    Google Scholar 

  158. Balthazar-Letawe D, Cleppe D, Coigne E, et al. Single daily dose of diclofenac retard tablets for the treatment of osteoarthritis. Acta Ther 1984; 10: 413–7

    Google Scholar 

  159. Fauvelle F, Nicolas P, Leon A, et al. Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. Biopharm Drug Disp 1991; 12: 411–24

    CAS  Google Scholar 

  160. Deakin M. Small bowel perforation associated with an excessive dose of slow release diclofenac sodium. BMJ 1988; 297: 488–9

    PubMed  CAS  Google Scholar 

  161. Carson J, Notis WM, Orris ES. Colonic ulceration and bleeding during diclofenac therapy [letter]. N Engl J Med 1989; 323: 135

    Google Scholar 

  162. Huber T, Ruchti C, Halter F. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report. Gastroenterology 1991; 100: 1119–22

    PubMed  CAS  Google Scholar 

  163. DAlteroche L, Boulier P, Barre I, et al. Les lesions coliquesdroites sont-elles specifiques des AINS a liberation prolongee? Gastroenterol Clin Biol 18: 1994; 1042–3

    CAS  Google Scholar 

  164. Sheers R, Williams WR. NSAIDs and gut damage [letter]. Lancet 1989; II: 1154

    Google Scholar 

  165. Fellows IW, Clarke JMF, Roberts PF. Non-steroidal anti-inflammatory drug-induced jejunal and colonic diaphragm disease: a report of two cases. Gut 1992; 33: 1424–6

    PubMed  CAS  Google Scholar 

  166. Haque S, Haswell JE, Dreznick JT, et al. A cecal diaphragm associated with the use of nonsteroidal anti-inflammatory drugs. J Clin Gastroenterol 1992; 15: 332–5

    PubMed  CAS  Google Scholar 

  167. Halter F, Weber B, Huber T, et al. Diaphragm disease of the ascending colon associated with sustained release diclofenac. J Clin Gastroenterol 1993; 16: 74–80

    PubMed  CAS  Google Scholar 

  168. Hudson N, Wilkinson MJ, Swannell AJ, et al. IIeo-cecal ulceration associated with the use of diclofenac slow release. Aliment Pharmacol Ther 1993; 7: 197–200

    PubMed  CAS  Google Scholar 

  169. Keating JP, Mcllwaine J. Simultaneous small and large bowel ulceration associated with short term NSAID use [letter]. N Z Med J 1993; 106: 438

    PubMed  CAS  Google Scholar 

  170. Baert F, Hart J, Blackstone MO. A case of diclofenac-induced colitis with focal granulomatous change. Am J Gastroenterol 1995; 90: 1871–3

    PubMed  CAS  Google Scholar 

  171. Bielecki JW, Gebbers JO, Filippini L. Segmentale dunndarmlasionen nach einnahme nicht-steroidaler antirheumatika. Dtsch Med Wochenschr 1995; 120: 436–41

    PubMed  CAS  Google Scholar 

  172. Gargot D, Chaussade S, Alteroche L, et al. Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. Am J Gastroenterol 1995; 90: 2035–8

    PubMed  CAS  Google Scholar 

  173. Choi VMI, Coates JE, Chooi J, et al Small bowel permeability: a variable effect of NSAIDs. Clin Invest Med 1995; 18: 357–61

    PubMed  CAS  Google Scholar 

  174. Reuter BK, Cirino G, Wallace JL. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 1994; 55(1): 1–8

    Google Scholar 

  175. Wallace JL, Reuter B, Cicala C, et al. A diclofenac derivative without ulcerogenic properties. Eur J Pharm 1994; 257: 249–55

    CAS  Google Scholar 

  176. Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107: 173–9

    PubMed  CAS  Google Scholar 

  177. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109–17

    PubMed  CAS  Google Scholar 

  178. Sacerdote P, Carrabba M, Galante A, et al. Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and diclofenac. Inflamm Res 1995; 44: 486–90

    PubMed  CAS  Google Scholar 

  179. Chlud K. Untersuchungen zur Wechselwirkung von diclofenac und glibenclamid. Z Rheumatol 1976; 35(9/10): 377–82

    PubMed  CAS  Google Scholar 

  180. Estevez F, Amaro G, Giusti M, et al. Diclofenac vs nimesulida en artrosis niveles plasmaticos y eficacia clinica. Medicina 1993; 53: 307–14

    PubMed  CAS  Google Scholar 

  181. Stierlin H, Faigle JW, Colombi A. Pharmacokinetics of diclofenac sodium (Voltaren) and metabolites in patients with impaired renal function. Scan J Rheumatol 1978; Suppl. 22: 30–5

    Google Scholar 

  182. Fauvelle F, Leon A, Niakate MT, et al. Pharmacokinetics of paracetamol, diclofenac and vidarabine during plasma exchange. Int J Artif Organs 1988; 11(3): 195–200

    PubMed  CAS  Google Scholar 

  183. Prieur AM. Efficacy and tolerance of diclofenac in chronic juvenile arthritis. Synthesis Rev Pediat 1984; 20: 325–7

    Google Scholar 

  184. Bird HA, Hill P, Leatham P, et al. A study to determine the clinical relevance of the pharmacokinetic interaction between aspirin and diclofenac. Agents Actions 1986; 18(3): 447–9

    PubMed  CAS  Google Scholar 

  185. Schumacher A, Caust-Tinnefeldt G, Geissler H et al. Voltaren: new findings. Bern: Hans Huber Publishers, 1982: 31–8

    Google Scholar 

  186. Branthwaite JP, Nicholls A. Cyclosporin and diclofenac interaction in rheumatoid arthritis [letter]. Lancet 1991; 337: 252

    PubMed  CAS  Google Scholar 

  187. Schumacher A, Geissler HE, Mutschler E, et al. Untersuchungen potenieller interaktionen von diclofenac-natrium (Voltaren®) mit antibiotika. Z Rheumatol 1983; 42: 25–7

    PubMed  CAS  Google Scholar 

  188. Rosak C, Schöffling K. Über den eunfluß von diclofenac aufdie glukosetoleranz von diabetikern. Med Welt 1977; 28(45): 1845–6

    PubMed  CAS  Google Scholar 

  189. Michot F, Ajdacic K, Glaus L. A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (Nicoumalone). J Int Med Res 1975; 3: 153–7

    PubMed  CAS  Google Scholar 

  190. Krzywanek HJ, Breddin K. Beeinflußt diclofenac die orale anti-koagulantientherapie und die plättchenaggregation? Med Welt 1977; 28(45): 1843–5

    PubMed  CAS  Google Scholar 

  191. Fischer M. Beeinflußt diclofenac die plasmatische gerinnung bei einer thromboembolienprophylaxe mit heparin/dihydroergotamin? Aktuel Rheumatol 1982; 7: 149–51

    Google Scholar 

  192. Gabrielli A, Leoni P, Danieli G. Methotrexate and non-steroidal anti-inflammatory drugs. BMJ 1987; 294: 776

    Google Scholar 

  193. Ahem M, Booth J, Loxton A, et al. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 1988; 15(9): 1356–60

    Google Scholar 

  194. Daly HM, Boyle J, Roberts CJC, et al. Interaction between methotrexate and non-steroidal anti-inflammatory drugs. Lancet 1986; I: 557

    Google Scholar 

  195. Deray G, Le Hoang P, Aupetit B, et al. Enhancement of cyclo-sporine A nephrotoxicity by diclofenac. Clin Nephrol 1987; 27: 213–4

    PubMed  CAS  Google Scholar 

  196. Harris KP, Jenkins D, Walls J. Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction. Transplantation 1988; 46(4): 598–9

    PubMed  CAS  Google Scholar 

  197. Astbury C, Taggart AJ, Zebouni LNP, et al. Single dose sulphasalazine pharmacokinetics in rheumatoid arthritis with and without concomitant NSAID therapy. Acta Pharmacol Toxicol 1986; 55Suppl. 5: 95

    Google Scholar 

  198. Reimann IW, Frolich JC. Effects of diclofenac on lithium kinetics. Clin Pharmacol Ther 1981; 30(3): 348–52

    PubMed  CAS  Google Scholar 

  199. Rau R, Georgiopoulous G, Neumann P, et al. Die beeinflussing des digoxinblutspiegels durch antirheumatika. Aktuel Rheumatol 1980; 5: 349–58

    Google Scholar 

  200. Schlumpf U. Der einfluss von diclofenac-natrium auf den Stoffwechsel von diabetikern unter qualitativer diät mit und ohne tolbutamid. Schweiz Med Wochenschr 1978; 1: 28–34

    Google Scholar 

  201. Reinicke C, Hippius M, Stiller K-J, et al. Diclofenac-natrium (Voltaren®) hat keinen einfluß auf die hepatische demethylierung von aminopyrin bei patienten mit rheumatischen erkrankungen. Aktuel Rheumatol 1983; 8: 10–3

    Google Scholar 

  202. Härkönen M, Ekblom-Kullberg S. Reversible deterioration of renal function after diclofenac in patient receiving triamterene. BMJ 1986; 293: 698–9

    Google Scholar 

  203. Koopmans PP, Thien TH, Gribnau FWJ. The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. Eur J Clin Pharmacol 1987; 31: 353–7

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1, Canada

    Neal M. Davies

  2. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    Keith E. Anderson

Authors
  1. Neal M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith E. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neal M. Davies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, N.M., Anderson, K.E. Clinical Pharmacokinetics of Diclofenac. Clin. Pharmacokinet. 33, 184–213 (1997). https://doi.org/10.2165/00003088-199733030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199733030-00003

Keywords

Search

Navigation